Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1, expanding the eligibility of ...

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...

Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...